Sera Prognostics, Inc. Announces the Resignation of Michael R. Foley, M.D., as Chief Medical Officer
July 31, 2023 at 08:57 am EDT
Share
On June 13, 2023, Michael R. Foley, M.D., notified Sera Prognostics, Inc. of his intention to resign from the position of Chief Medical Officer of the Company, effective as of June 30, 2023, and has moved to a consulting role. Effective July 1, 2023, the Company entered into a consulting agreement (the Consulting Agreement") with Dr. Foley, pursuant to which Dr. Foley agreed to provide certain consulting services to the Company upon its request in exchange for payment of $500 per hour, up to 12 hours per week, and continued vesting of his equity awards pursuant to their terms during the term of the Consulting Agreement.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
SERA PROGNOSTICS, INC. 
